Live
- Judiciary Plays a Key Role in the Indian Constitution - Senior Civil Judge A. Sri Devi
- Karnataka BJP Stands Strong Against Waqf Board Misuse
- Keerthy Suresh in sultry avatar for Bollywood debut ‘Baby John’
- Ram Charan pre-look for ‘RC16’ sets internet on fire
- BBMP Accused Of Misappropriating ₹46,300 Crore In Public Funds
- Tensions Mount In Manipur As Missing Meitei Man Sparks Protests
- Allahabad High Court To Review Dual Citizenship Allegations Against Rahul Gandhi
- Tollywood mourns the loss of lyricist Kulasekhar
- Labourer's Mortal Remains Negligently Disposed Four Arrests Made Thus Far
- How Businesses Can Encourage Innovation And Collaboration In Diverse Workforce
Glenmark Pharma unveils asthma drug Indamet
It offers an affordable treatment option for adults and adolescents 12 yrs of age and older suffering from uncontrolled asthma
New Delhi: Glenmark Pharmaceuticals on Thursday said it has launched a novel fixed-dose combination (FDC) drug in the country for patients with uncontrolled asthma. The Mumbai-based drug major has launched - Indacaterol + Mometasone FDC under the brand name Indamet.
The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg and 320 mcg to be taken once daily. "Respiratory is a key focus area for Glenmark, and the company leads from the front in providing access to the latest treatment options to patients.
"We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India, offering an affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma," Glenmark Pharmaceuticals Group Vice President & Head (India Formulations) Alok Malik said in a statement.
The drug maker is the first company in India to market the FDC of Indacaterol, a long-acting beta-agonist and Mometasone Furoate, an inhaled corticosteroid, approved by the DCGI (Drug Controller General of India), the company noted. Asthma affects more than 34 million people in India, causing thousands of deaths every year.
